For example, CDK4/6 is hyperactivated in many human cancers as a result of overexpression of positive regulators such as CYCLIN D, inactivation of INK4 and CIP/KIP inhibitors, or deletion and/or epigenetic alterations of substrates such as RB [reviewed in 1, 118, 119]. This evidence concerns the gene RB1 and cancer.